Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
43.38 USD -1.65% Intraday chart for Ultragenyx Pharmaceutical Inc. -14.44% -9.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ
Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement' MT
Sector Update: Health Care Stocks Advance Premarket Monday MT
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call
Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 CI
JPMorgan Adjusts Price Target on Ultragenyx Pharmaceutical to $92 From $88, Maintains Overweight Rating MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 04:20 PM
Ultragenyx Pharmaceutical Insider Sold Shares Worth $574,644, According to a Recent SEC Filing MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:10 AM
Canaccord Genuity Adjusts Ultragenyx Pharmaceutical's Price Target to $111 From $110, Keeps Buy Rating MT
Sector Update: Health Care Stocks Gain Pre-Bell Friday MT
Wedbush Lifts Ultragenyx Pharmaceutical's PT to $48 From $47, Notes Fuller Catalyst Lineup for 2024; Keeps Neutral Rating MT
Ultragenyx Pharmaceutical Q4 Loss Narrows, Revenue Rises; 2024 Revenue Guidance Set MT
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 15, 2024
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q4 Revenue $127.4M MT
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024 CI
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Ultragenyx Says UX111 Treatment Results Correlate With Improved Cognitive Function MT
Ultragenyx Pharmaceutical Inc. Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) CI
Ultragenyx Pharmaceutical's Angelman Syndrome Potential Treatment Receives European Medicines Agency Priority Designation MT
Ultragenyx Pharmaceutical Inc. Receives PRIME Designation from European Medicines Agency for GTX-102 for the Treatment of Angelman Syndrome CI
Ultragenyx Pharmaceutical Doses All Patients in Stage 1 Cohorts of Trial Evaluating Wilson Disease Therapy MT
Ultragenyx Pharmaceutical Inc. Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease CI
Transcript : Ultragenyx Pharmaceutical Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:00 PM
Chart Ultragenyx Pharmaceutical Inc.
More charts
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
43.38 USD
Average target price
90.05 USD
Spread / Average Target
+107.58%
Consensus
  1. Stock Market
  2. Equities
  3. RARE Stock
  4. News Ultragenyx Pharmaceutical Inc.
  5. Canaccord Genuity Adjusts Ultragenyx Pharmaceutical's Price Target to $111 From $110, Keeps Buy Rating